Suppr超能文献

抗A组链球菌抗体:小鼠脾细胞体外激活与杂交后的产生

Antistreptococcal group A antibodies: production after in vitro activation and hybridization of mouse spleen cells.

作者信息

Herbst H, Braun D G

出版信息

Ann Immunol (Paris). 1981 Jan-Feb;132C(1):87-100. doi: 10.1016/0769-2625(81)90009-x.

Abstract

Streptococcal group A polysaccharide-specific antibodies were raised by the method of somatic cell hybridization. Spleen cells of experimentally unprimed BALB/c and C57BL/6 mice were activated in vitro by the streptococcal vaccine and fused with the Sp2/0-Ag14 line at times o, 35, 70, and 105 h thereafter. Hybridomas were obtained at all times independent of the addition of thymocyte-conditioned medium. Occurrence of specific hybridomas for the T cell-dependent A-CHO, however, required activation for greater than 35 h. Low responder C57BL/6 splenocytes fused at considerably higher fusion efficiency to yield specific hybridomas than high responder spleen cells 105 h after activation by antigen. The isotypes of A-CHO-specific antibodies comprised predominantly mu and kappa polypeptides; however, gamma 3, alpha, and gamma polypeptide chains were also identified. All specific antibodies were agglutinating the group A streptococcal cells; this agglutination was fully inhibited by the addition of 1% N-acetyl-D-glucosamine, the immune determinant sugar of the A-CHO. Three hybridomas obtained by fusion of BALB/c splenocytes 105 h after activation were cloned and grown as tumours in the peritoneal cavity of BALB/c mice. The monoclonal antibodies in the ascites did not precipitate the A-CHO but continued to agglutinate group A streptococcal cells in a hapten inhibitable fashion with different specificity profiles. Antibody from clone 21S36.1 was coprecipitable upon addition of A-CHO with a gamma G3 monoclonal hybridoma-derived antibody in a ratio of 1/7 while the other two monoclonal gamma M antibodies and the S117 myeloma protein were not. The result suggests that antibody 21S36.1 recognizes one chain terminal determinant of the A-CHO.

摘要

通过体细胞杂交方法制备了抗A群链球菌多糖特异性抗体。将未经实验致敏的BALB/c和C57BL/6小鼠的脾细胞用链球菌疫苗在体外激活,然后在0、35、70和105小时与Sp2/0-Ag14细胞系融合。无论是否添加胸腺细胞条件培养基,在所有时间点均获得了杂交瘤。然而,对于依赖T细胞的A-CHO产生特异性杂交瘤,需要激活超过35小时。低反应性的C57BL/6脾细胞在激活105小时后融合效率显著高于高反应性脾细胞,从而产生特异性杂交瘤。A-CHO特异性抗体的同种型主要包括μ和κ多肽;然而,也鉴定出了γ3、α和γ多肽链。所有特异性抗体均能凝集A群链球菌细胞;添加1%的N-乙酰-D-葡萄糖胺(A-CHO的免疫决定糖)可完全抑制这种凝集。将激活105小时后的BALB/c脾细胞融合获得的三个杂交瘤进行克隆,并在BALB/c小鼠腹腔内作为肿瘤生长。腹水中的单克隆抗体不沉淀A-CHO,但继续以半抗原可抑制的方式凝集A群链球菌细胞,且具有不同的特异性谱。添加A-CHO后,克隆21S36.1的抗体可与γG3单克隆杂交瘤衍生抗体以1/7的比例共沉淀,而其他两种单克隆γM抗体和S117骨髓瘤蛋白则不能。结果表明,抗体21S36.1识别A-CHO的一个链末端决定簇。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验